Dr Marc Therrien is working toward blocking a cancer-driving protein.
Mutations in BRAF – a protein that promotes cell growth and division – can cause it to become overactive and lead to cancer. Dr Marc Therrien and his team were the first to determine the 3-D structure of BRAF in its inactive “off” state, which provided important insight into how BRAF works and can be altered by mutations. Through an industry collaboration, the team is using this knowledge to develop novel BRAF inhibitors as potential anticancer drugs.
Learn more about the impact of our research, supported by your donations.
Reference: Nature Structural & Molecular Biology, January 2015